SAN MATEO, Calif., June 16, 2008 (PRIME NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) announced today the successful completion of its first clinical study utilizing a novel melanoma treatment. This treatment consisted of dosing patients with a monoclonal antibody labeled with a radio-isotope. The Company owns exclusive worldwide commercial rights to this technology, which it licensed from Albert Einstein College of Medicine.
